All In Biotech

Drug Trial Radar · NCT03019406

A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa

An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of Avalglucosidase Alfa (NeoGAA, GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response

Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

22

Actual

Start

Oct 12, 2017

Primary completion

Sep 30, 2019

Study completion Aug 10, 2027

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jan 12, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multi-stage, phase 2, open-label, multicenter, multinational, ascending dose cohort, repeated intravenous (IV) infusion study of avalglucosidase alfa in pediatric patients with Infantile-Onset Pompe Disease (IOPD) who have been previously treated with alglucosidase alfa for a minimum of 6 months immediately prior to study entry and have demonstrated clinical decline or unsatisfactory clinical response.

Conditions

  • Glycogen Storage Disease Type II-Pompe's Disease

Interventions

  • Avalglucosidase alfa (GZ402666)Drug

    Pharmaceutical form: powder for concentrate for solution for infusion, Route of administration: IV

  • Alglucosidase alfa (GZ419829)Drug

    Pharmaceutical form: powder for concentrate for solution for infusion, Route of administration: IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI)Time frame: From Baseline to Week 25
  2. PAP: Number of Participants With Infusion-associated Reactions (IARs)Time frame: From Baseline to Week 25

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • Regional Medical Genetics Center of New York Site Number : 8400002

    Valhalla, New York

  • Duke University Medical Center Site Number : 8400001

    Durham, North Carolina

  • Seattle Childrens Hospital and Regional Medical Center- Site Number : 8400005

    Seattle, Washington

  • Investigational Site Number : 2500004

    Nantes, France

  • Investigational Site Number : 2500003

    Paris, France

  • Investigational Site Number : 2500002

    Paris, France

  • Investigational Site Number : 2500001

    Tours, France

  • Investigational Site Number : 3920001

    Fuchu-shi, Tokyo, Japan

  • Investigational Site Number : 3920002

    Fuchu-shi, Tokyo, Japan

  • Investigational Site Number : 1580001

    Hsinchu, Taiwan

  • Investigational Site Number : 8260002

    Manchester, United Kingdom

  • Investigational Site Number : 8260001

    London, London, City of, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.